ACTIVE A-Studie: Vermindertes Schlaganfallrisiko durch zusätzliche Gabe von Clopidogrel

ISSN： 1864-9718

Source： Der Kardiologe, Vol.3, Iss.4, 2009-08, pp. : 331-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antikoagulation bei Vorhofflimmern: ACTIVE-Studie (Aterial fibrillation Clopidogrel Trail with Irbesartan for prevention of Vascular Events)

By Meinertz T.

Der Internist, Vol. 48, Iss. 8, 2007-08 ,pp. : 874-875

Springer Publishing Company

Access to resources Recommend Favorite

Unter welchen Bedingungen ist die subkutane Gabe von Flüssigkeit indiziert?

By Bausewein C.

Der Internist, Vol. 48, Iss. 4, 2007-04 ,pp. : 439-441

Springer Publishing Company

Access to resources Recommend Favorite

Interaktion von Statinen mit Clopidogrel

By Scheidt W.

Der Internist, Vol. 45, Iss. 3, 2004-03 ,pp. : 363-365

Springer Publishing Company

Access to resources Recommend Favorite

Prävention atherothrombotischer Ereignisse: CHARISMA-Studie (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance)

By Erdmann E.

Der Internist, Vol. 47, Iss. 12, 2006-12 ,pp. : 1295-1297

Springer Publishing Company

Access to resources Recommend Favorite

Keine Varizella-Zoster-Virus-Reaktivierung nach Infliximab-Gabe zur Behandlung von Plaque-Psoriasis

Karger Kompass Dermatologie, Vol. 3, Iss. 2, 2015-09 ,pp. : 84-85

Karger

Access to resources Recommend Favorite